Study S000128

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07309094
Acronym: ADIPO-CKD
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 250
Start: 2023-09-15
Primary completion: 2027-07-31
Lead sponsor: Cardenal Herrera University
Conditions: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2
Interventions: DRUG:GLP-1 receptor agonist; DRUG:SGLT2 inhibitor; DRUG:Tirzepatide; DRUG:Other drugs
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Ultrasonography change in perirenal adipose tissue thickness [16 months]
Change in estimated glomerular filtration rate [16 months]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017113	Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease. Checa-Ros A, Journal of clinical medicine	2026	Nonrandomized study	PMID 42194603 DOI	cites ClinicalTrials.gov:NCT07309094
R0056611	The Effects of GLP-1RA-Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD Patients. Checa-Ros A, Diabetes, obesity & metabolism	2026	Nonrandomized study	PMID 42865317 DOI	cites ClinicalTrials.gov:NCT07309094
R0005970	Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice. Zhao L, Endocrine	2024	Preclinical	PMID 38378894 DOI	registry reference BACKGROUND:38378894
R0019647	Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. Perkovic V, The New England journal of medicine	2024	Randomized trial	PMID 38785209 DOI	registry reference BACKGROUND:38785209
R0008562	GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. Giugliano D, Diabetes, obesity & metabolism	2019	Systematic review	PMID 31373167 DOI	registry reference BACKGROUND:31373167
R0028200	GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway. Ying Y, Journal of molecular endocrinology	2015	Preclinical	PMID 26386043 DOI	registry reference BACKGROUND:26386043
R0014123	Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Carraro-Lacroix LR, American journal of physiology. Renal physiology	2009	Preclinical	PMID 19776173 DOI	registry reference BACKGROUND:19776173